Benzinga | Jan 7, 2022 01:02PM EST

908 Devices Reports GlaxoSmithKline Purchased An Added REBEL Cell Culture Media Analyzer, No Terms Disclosed

908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE:GSK) has purchased an additional REBEL(tm) cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams.

"We are pleased that GSK has once again chosen our REBEL desktop device as part of its process development efforts to bring promising therapeutics to market," said Dr. Kevin J. Knopp, CEO and co-founder of 908 Devices. "The REBEL analyzer enables our biopharma customers to make critical decisions on optimizing cell cultures in minutes, and its small desktop footprint fits alongside bioreactors in process development labs."

908 Devices notes there are now 15 customers owning multiple REBEL devices, more than double from one year ago. In addition, all 20 of the top 20 pharmaceutical companies are now using the company's desktop devices, which include REBEL and ZipChip(r), in their development process.